A Principal in PwC’s Pharmaceutical Industry Group, Tina was head of R&D Operations at RNA modulation company Prosensa Therapeutics, a rare disease spin out from Leiden University (IPO NASDAQ: [RNA] 2013, acquired by Biogen). From 2016 Tina led Edinburgh-based MedAnnex Ltd and aTen Therapeutics Ltd, working in annexin-A1 and angiotensin modulation. Medannex Ltd completed an £11 million funding round in 2020. Tina is a Trustee and previous Chair of the rare disease patient organisation Action Duchenne, she chairs the patient-led R&D community of interest for the Pistoia Alliance and sits on the steering committee for the Pistoia Alliance collaboration with DiMe, the Digital Medicine Society.
As an advocate for meaningful outcome measures, Tina is encouraged by the new wealth of disease registries and patient-contributed data. She is interested to drive translational R&D processes and technologies that can use new data sources to design better measures and more useful therapies.